Dr Roger F Johnson, MD | |
901 Saint Marys Dr Ste 200, Evansville, IN 47714 | |
(812) 485-6030 | |
Not Available |
Full Name | Dr Roger F Johnson |
---|---|
Gender | Male |
Speciality | Pulmonary Disease |
Experience | 25 Years |
Location | 901 Saint Marys Dr Ste 200, Evansville, Indiana |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1780624742 | NPI | - | NPPES |
64056310 | Medicaid | KY | |
000000489925 | Other | IN | ANTHEM |
200821580 | Medicaid | IN | |
P00377506 | Other | IN | RAILROAD MEDICARE |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
207RC0200X | Internal Medicine - Critical Care Medicine | 01061986A (Indiana) | Secondary |
207RP1001X | Internal Medicine - Pulmonary Disease | 01061986A (Indiana) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Ascension St Vincent Evansville | Evansville, IN | Hospital |
Daviess Community Hospital | Washington, IN | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
St Marys Medical Group Llc | 1153493341 | 198 |
News Archive
An innovative program that cut cardiac deaths by 73 percent by linking coronary artery disease patients and teams of pharmacists, nurses, primary care doctors, and cardiologists with an electronic health record also kept the patients healthy two years after they left the program by keeping them in touch with their care givers electronically, according to a randomized study by Kaiser Permanente published in The American Journal of Managed Care this month.
Cell Therapeutics, Inc. has received fast track designation from the U.S. Food and Drug Administration (FDA) for pixantrone, a novel anthracenedione, being investigated for the potential treatment of relapsed, aggressive non-Hodgkin's lymphoma (NHL).
Fujitsu Laboratories Ltd., the Insight Centre for Data Analytics, a data analytics research institution based in Ireland, and Fujitsu (Ireland) Limited today announced the development of a technology that makes it possible to predict large volumes of unknown chemical reactions, about twice as many as the conventional procedure.
A team of UC Davis investigators has found that a genetic mutation may play an important role in the development of prostate cancer. The mutation of the so-called p53 (or Tp53) gene was previously implicated in late disease progression, but until now has never been shown to act as an initiating factor. The findings may open new avenues for diagnosing and treating the disease.
Oraya Therapeutics, Inc. announced today that the Oraya Therapy Stereotactic Radiotherapy for the treatment of wet age-related macular degeneration (AMD) is now available at Optegra Manchester Eye Hospital, becoming the second facility in the UK to provide the therapy.
› Verified 8 days ago
Entity Name | St Marys Medical Group Llc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1164852539 PECOS PAC ID: 1153493341 Enrollment ID: O20140313001275 |
News Archive
An innovative program that cut cardiac deaths by 73 percent by linking coronary artery disease patients and teams of pharmacists, nurses, primary care doctors, and cardiologists with an electronic health record also kept the patients healthy two years after they left the program by keeping them in touch with their care givers electronically, according to a randomized study by Kaiser Permanente published in The American Journal of Managed Care this month.
Cell Therapeutics, Inc. has received fast track designation from the U.S. Food and Drug Administration (FDA) for pixantrone, a novel anthracenedione, being investigated for the potential treatment of relapsed, aggressive non-Hodgkin's lymphoma (NHL).
Fujitsu Laboratories Ltd., the Insight Centre for Data Analytics, a data analytics research institution based in Ireland, and Fujitsu (Ireland) Limited today announced the development of a technology that makes it possible to predict large volumes of unknown chemical reactions, about twice as many as the conventional procedure.
A team of UC Davis investigators has found that a genetic mutation may play an important role in the development of prostate cancer. The mutation of the so-called p53 (or Tp53) gene was previously implicated in late disease progression, but until now has never been shown to act as an initiating factor. The findings may open new avenues for diagnosing and treating the disease.
Oraya Therapeutics, Inc. announced today that the Oraya Therapy Stereotactic Radiotherapy for the treatment of wet age-related macular degeneration (AMD) is now available at Optegra Manchester Eye Hospital, becoming the second facility in the UK to provide the therapy.
› Verified 8 days ago
Mailing Address | Practice Location Address |
---|---|
Dr Roger F Johnson, MD 901 Saint Marys Dr Ste 200, Evansville, IN 47714-0509 Ph: () - | Dr Roger F Johnson, MD 901 Saint Marys Dr Ste 200, Evansville, IN 47714 Ph: (812) 485-6030 |
News Archive
An innovative program that cut cardiac deaths by 73 percent by linking coronary artery disease patients and teams of pharmacists, nurses, primary care doctors, and cardiologists with an electronic health record also kept the patients healthy two years after they left the program by keeping them in touch with their care givers electronically, according to a randomized study by Kaiser Permanente published in The American Journal of Managed Care this month.
Cell Therapeutics, Inc. has received fast track designation from the U.S. Food and Drug Administration (FDA) for pixantrone, a novel anthracenedione, being investigated for the potential treatment of relapsed, aggressive non-Hodgkin's lymphoma (NHL).
Fujitsu Laboratories Ltd., the Insight Centre for Data Analytics, a data analytics research institution based in Ireland, and Fujitsu (Ireland) Limited today announced the development of a technology that makes it possible to predict large volumes of unknown chemical reactions, about twice as many as the conventional procedure.
A team of UC Davis investigators has found that a genetic mutation may play an important role in the development of prostate cancer. The mutation of the so-called p53 (or Tp53) gene was previously implicated in late disease progression, but until now has never been shown to act as an initiating factor. The findings may open new avenues for diagnosing and treating the disease.
Oraya Therapeutics, Inc. announced today that the Oraya Therapy Stereotactic Radiotherapy for the treatment of wet age-related macular degeneration (AMD) is now available at Optegra Manchester Eye Hospital, becoming the second facility in the UK to provide the therapy.
› Verified 8 days ago
Corinne Mbakop, MD Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 533 W Columbia St, Evansville, IN 47710 Phone: 812-492-5202 Fax: 812-450-8102 | |
Maqbool A Ahmed, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 421 Chestnut St, Evansville, IN 47713 Phone: 812-426-9411 Fax: 812-426-9503 | |
Dr. Jerry Becker, M.D. Pulmonary Disease Medicare: Not Enrolled in Medicare Practice Location: 415 W Columbia St, Evansville, IN 47710 Phone: 812-464-9133 Fax: 812-464-0559 | |
Mubashir A Zahid, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 520 Mary St Ste 230, Evansville, IN 47710 Phone: 812-450-8600 Fax: 812-450-8151 | |
Dr. Richard A Wepsic, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 520 Mary St., Suite 230, Evansville, IN 47710 Phone: 812-464-9133 Fax: 812-464-0559 | |
Dr. Jessica L Jeffries, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 519 Harriet St, Evansville, IN 47710 Phone: 812-450-7720 Fax: 812-450-7730 | |
Dr. Bachar Malek, M.D. Pulmonary Disease Medicare: Accepting Medicare Assignments Practice Location: 4972 Lincoln Ave, Suit 101, Evansville, IN 47715 Phone: 812-402-3700 Fax: 812-402-4611 |